

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5771000

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
I-MAB	10/14/2019
RECEIVING PARTY DATA	
Name:	I-MAB BIOPHARMA US LIMITED
Street Address:	9801 WASHINGTONIAN BLVD
Internal Address:	SUITE 710
City:	GAITHERSBURG
State/Country:	MARYLAND
Postal Code:	20878
PROPERTY NUMBERS Total: 10	
Property Type	Number
Application Number:	16069144
Application Number:	15744737
Application Number:	16100019
Application Number:	16100065
Application Number:	16069487
Application Number:	15744734
Application Number:	16100063
Application Number:	16489970
Application Number:	16482023
Application Number:	16483870
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	bdinh@smrh.com, svipdocketing@smrh.com
Correspondent Name:	SHEPPARD MULLIN RICHTER & HAMPTON LLP
Address Line 1:	379 LYTTON AVENUE
Address Line 2:	ALEX Y. NIE
Address Line 4:	PALO ALTO, CALIFORNIA 94301

NAME OF SUBMITTER:	ALEX Y. NIE
SIGNATURE:	/Alex Y. Nie/
DATE SIGNED:	10/15/2019
Total Attachments: 8 source=Assignment-Worldwide Except China-SM#page1.tif source=Assignment-Worldwide Except China-SM#page2.tif source=Assignment-Worldwide Except China-SM#page3.tif source=Assignment-Worldwide Except China-SM#page4.tif source=Assignment-Worldwide Except China-SM#page5.tif source=Assignment-Worldwide Except China-SM#page6.tif source=Assignment-Worldwide Except China-SM#page7.tif source=Assignment-Worldwide Except China-SM#page8.tif	

ASSIGNMENT – WORLDWIDE EXCEPT CHINA

For good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged,

I-Mab
Grand Pavilion, Hibiscus Way, 802 West Bay Road
PO Box 31119
Grand Cayman, KY1-1205 Cayman Islands

registered in the Cayman Islands (hereinafter referred to as "ASSIGNOR") has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto

I-Mab Biopharma US Limited
9801 Washingtonian Blvd, Suite 710
Gaithersburg, MD 20878
USA

registered in the state of Maryland, the United States (hereinafter referred to as "ASSIGNEE"), its successors and assigns, the full and exclusive right, title and interest for all countries **except the People's Republic of China, including Hong Kong and Macau with respect to Chinese patents and patent applications extended thereto ("China")** in and to the inventions described and claimed in the patent applications and issued patents referenced in Schedule A hereof, as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent in all countries **except China** for the above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in all countries **except China**, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, (e) all post-grant proceedings including but not limited to post-grant review, *ex parte* reexamination and inter partes review, and (f) the right to claim for any of said applications the full benefits and priority rights under the Patent Cooperation Treaty, the Paris Convention and any other international agreement; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries **except China** on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.


ASSIGNOR HEREBY GRANTS ASSIGNEE the right to sue for past, present and future infringement, and the right to collect and receive any damages, royalties, or settlement for such past, present and future infringements and any and all causes of action relating to any of the inventions or discoveries described in this invention.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the patent offices or equivalent authorities to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.


ASSIGNOR:

For: I-Mab

Signature: 
Name: Jingwu Zang
Title: CEO
Date: October 14, 2019

ASSIGNEE:

For: I-Mab Biopharma US Limited

Signature: 
Name: Jingwu Zang
Title: CEO
Date: October 14, 2019

SCHEDULE A

Attorney Ref. No.	Jurisdiction	Title	Application Number	Filing Date	Patent Number	Issue Date
54LW-250265-AU	Australia	ANTI-CD73 ANTIBODIES AND USES THEREOF	2018213549	20-May-19		
54LW-250265-BR	Brazil	ANTI-CD73 ANTIBODIES AND USES THEREOF	BR112019012040-8	12-Jun-19		
54LW-250265-CA	Canada	ANTI-CD73 ANTIBODIES AND USES THEREOF	3045376	29-May-19		
54LW-250265-CL	Chile	ANTI-CD73 ANTIBODIES AND USES THEREOF	201901756	21-Jun-19		
54LW-250265-CO	Colombia	ANTI-CD73 ANTIBODIES AND USES THEREOF	NC2019/0006657	21-Jun-19		
54LW-250265-EA	Eurasia Patent Office	ANTI-CD73 ANTIBODIES AND USES THEREOF	201991099	30-May-19		
54LW-250265-EP	European Patent Office	ANTI-CD73 ANTIBODIES AND USES THEREOF	18733153-3	23-Jan-18		
54LW-250265-HK	Hong Kong, China	ANTI-CD73 ANTIBODIES AND USES THEREOF	19121375	22-Mar-19		
54LW-250265-ID	Indonesia	ANTI-CD73 ANTIBODIES AND USES THEREOF	PID201905985	15-Jul-19		
54LW-250265-IL	Israel	ANTI-CD73 ANTIBODIES AND USES THEREOF	267942	9-Jul-19		
54LW-250265-IN	India	ANTI-CD73 ANTIBODIES AND USES THEREOF	201917921876	3-Jun-19		
54LW-250265-JP	Japan	ANTI-CD73 ANTIBODIES AND USES THEREOF	2019-528825	29-May-19		
54LW-250265-KR	Republic of Korea	ANTI-CD73 ANTIBODIES AND USES THEREOF	10-2018-7022273	23-Jan-18		
54LW-250265-KR2	Republic of Korea	ANTI-CD73 ANTIBODIES AND USES THEREOF	10-2019-7025714	2-Sep-19		
54LW-250265-MX	Mexico	ANTI-CD73 ANTIBODIES AND USES THEREOF	MX/a/2019/008758	23-Jul-19		
54LW-250265-MY	Malaysia	ANTI-CD73 ANTIBODIES AND USES THEREOF	P12019003100	29-May-19		
54LW-250265-NZ	New Zealand	ANTI-CD73 ANTIBODIES AND USES THEREOF	753714	20-May-19		
54LW-250265-PE	Peru	ANTI-CD73 ANTIBODIES AND USES THEREOF	003312-2019/DIN	23-Jun-19		
54LW-250265-PH	Philippines	ANTI-CD73 ANTIBODIES AND USES THEREOF	1-2019-350087	20-May-19		
54LW-250265-SG	Singapore	ANTI-CD73 ANTIBODIES AND USES THEREOF	112019044955	21-May-19		
54LW-250265-UA	Ukraine	ANTI-CD73 ANTIBODIES AND USES THEREOF	a201906284	4-Jun-19		
54LW-250265-US	United States of	ANTI-CD73 ANTIBODIES AND USES THEREOF	16/069144	10-Jul-18		

54LW-250265-WO	America	ANTI-CD73 ANTIBODIES AND USES THEREOF	PCT/CN2017/072445	24-Jan-17	
54LW-250265-WO2	PCT	ANTI-CD73 ANTIBODIES AND USES THEREOF	PCT/CN2018/073746	23-Jan-18	
54LW-250265-ZA	South Africa	ANTI-CD73 ANTIBODIES AND USES THEREOF	2019/04619	15-Jul-19	
54LW-250266-AU	Australia	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	2017284632	13-Jun-17	
54LW-250266-BR	Brazil	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	BR112018075737-3	13-Jun-17	
54LW-250266-CA	Canada	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	3027209	13-Jun-17	
54LW-250266-CL	Chile	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	201803583	13-Jun-17	
54LW-250266-CO	Colombia	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	NC2019/0013500	13-Jun-17	
54LW-250266-EA	Eurasia Patent Office	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	201892748	13-Jun-17	
54LW-250266-EP	European Patent Office	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	17812701.5	13-Jun-17	
54LW-250266-ID	Indonesia	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	P90201900261	13-Jun-17	
54LW-250266-IL	Israel	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	263509	13-Jun-17	
54LW-250266-IN	India	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	201917000386	13-Jun-17	
54LW-250266-JP	Japan	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	2018-569190	10-Dec-18	
54LW-250266-KR	Republic of Korea	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	10-2018-7609566	13-Jun-17	27-Jun-19
54LW-250266-KR2	Republic of Korea	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	10-2019-7018708	27-Jun-19	
54LW-250266-MX	Mexico	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	MX/s/2018/015584	13-Jun-17	
54LW-250266-MY	Malaysia	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	P12018002548	13-Jun-17	
54LW-250266-NZ	New Zealand	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	749019	13-Jun-17	
54LW-250266-PE	Peru	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	003214-2018/DIK	13-Jun-17	
54LW-250266-PH	Philippines	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	1-2018-502623	12-Dec-18	
54LW-250266-SG	Singapore	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	1.1201811003P	13-Jun-17	
54LW-250266-UA	Ukraine	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	a 2018 13072	13-Jun-17	
54LW-250266-US	United States of	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	15/744737	12-Jan-18	28-Aug-18
			10059769		

541W-250266-US2	America United States of America	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	16/100019	9-Aug-18	10208119	19-Feb-19
541W-250266-US3	United States of America	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	16/100065	9-Aug-18		
541W-250266-WO	PCT	Anti-PD-L1 Antibodies and Uses Thereof	PCT/CN2017/072566	25-Jan-17		
541W-250266-WO2	PCT	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	PCT/CN2017/088033	13-Jun-17		
541W-250266-ZA	South Africa	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	2019/00193	13-Jun-17		
541W-258155-AU	Australia	ANTI-LAG-3 ANTIBODIES AND USES THEREOF	2018226288	23-Aug-19		
541W-258155-CA	Canada	ANTI-LAG-3 ANTIBODIES AND USES THEREOF		19-Aug-19		
541W-258155-EP	European Patent Office	ANTI-LAG-3 ANTIBODIES AND USES THEREOF	18733152.5	22-Feb-18		
541W-258155-IL	Israel	ANTI-LAG-3 ANTIBODIES AND USES THEREOF	268734	15-Aug-19		
541W-258155-IN	India	ANTI-LAG-3 ANTIBODIES AND USES THEREOF	201917035545	4-Sep-19		
541W-258155-JP	Japan	ANTI-LAG-3 ANTIBODIES AND USES THEREOF	2019-544658	16-Aug-19		
541W-258155-KR	Republic of Korea	ANTI-LAG-3 ANTIBODIES AND USES THEREOF	10-2018-7022954	22-Feb-18		
541W-258155-KR2	Republic of Korea	ANTI-LAG-3 ANTIBODIES AND USES THEREOF	10-2019-7014275	17-May-19		
541W-258155-NZ	New Zealand	ANTI-LAG-3 ANTIBODIES AND USES THEREOF	756676	23-Aug-19		
541W-258155-SG	Singapore	ANTI-LAG-3 ANTIBODIES AND USES THEREOF	11201907561P	16-Aug-19		
541W-258155-US	United States of America	ANTI-LAG-3 ANTIBODIES AND USES THEREOF	16/059487	11-Jul-18		
541W-258155-WO	PCT	Anti-LAG3 antibodies and uses thereof	PCT/CN2017/074365	22-Feb-19		
541W-258155-WO2	PCT	ANTI-LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) ANTIBODIES, AND USES THEREOF	PCT/CN2017/038570	16-Jun-17		
541W-258155-WO3	PCT	ANTI-LAG-3 ANTIBODIES AND USES THEREOF	PCT/CN2016/076940	22-Feb-18		
541W-258155-ZA	South Africa	ANTI-LAG-3 ANTIBODIES AND USES THEREOF	2019/05790	2-Sep-19		
541W-258793-AU	Australia	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	2017328383	22-Feb-19		

541W-258793-BR	Brazil	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	BR112019005274-7	18-Mar-19	
541W-258793-CA	Canada	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	3036599	11-Mar-19	
541W-258793-CL	Chile	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	201900702	18-Mar-19	
541W-258793-CO	Colombia	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	NC2019/0002550	19-Mar-19	
541W-258793-EA	Eurasia Patent Office	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	201990493	12-Mar-19	
541W-258793-EP	European Patent Office	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	17840546	18-Sep-17	
541W-258793-ID	Indonesia	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	P06201903276	18-Apr-19	
541W-258793-IL	Israel	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	265331	13-Mar-19	
541W-258793-IN	India	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	201917010087	15-Mar-19	
541W-258793-IP	Japan	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	2019-511372	25-Feb-19	
541W-258793-KR	Republic of Korea	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	10-2018-7009572	18-Sep-17	1953706
541W-258793-KZ	Republic of Korea	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	10-2019-7005546	25-Feb-19	
541W-258793-MX	Mexico	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	MX/a/2019/003019	14-Mar-19	
541W-258793-MY	Malaysia	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	P12019001075	27-Feb-19	
541W-258793-NZ	New Zealand	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	750976	22-Feb-19	
541W-258793-PE	Peru	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	000664-2019/DIN	18-Mar-19	
541W-258793-PH	Philippines	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	1-2019-500434	28-Feb-19	
541W-258793-SG	Singapore	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	11201901789W	28-Feb-19	
541W-258793-UA	Ukraine	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	a2019 01976	27-Feb-19	

54LW-258793-US	United States of America	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	15/744734	12-Jan-18	
54LW-258793-US2	United States of America	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	16/100663	9-Aug-18	
54LW-258793-WO	PCT	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	PCT/CN2017/102057	18-Sep-17	
54LW-258793-ZA	South Africa	ANTI-GM-CSF ANTIBODIES AND USES THEREOF	2019/01835	25-Mar-19	
54LW-263233-AU	Australia	MODIFIED CK AND CH1 DOMAINS	2019203917	5-Jun-19	
54LW-263233-EP	European Patent Office	MODIFIED CK AND CH1 DOMAINS	19740101.3	21-Jun-19	
54LW-263233-KR	Republic of Korea	MODIFIED CK AND CH1 DOMAINS	10-2019-7022000	25-Jul-19	
54LW-263233-US	United States of America	MODIFIED CK AND CH1 DOMAINS	16/489970	29-Aug-19	
54LW-263233-WO	PCT	MODIFIED CK AND CH1 DOMAINS	PCT/CN2018/072564	15-Jan-18	
54LW-263233-WO2	PCT	MODIFIED CK AND CH1 DOMAINS	PCT/CN2019/071740	15-Jan-19	
54LW-267746-AU	Australia	ANTI-PD-L1 ANTIBODY AND IL-7 FUSIONS	2019203918	5-Jun-19	
54LW-267746-EP	European Patent Office	ANTI-PD-L1 ANTIBODY AND IL-7 FUSIONS	19750102.1	21-Jan-19	
54LW-267746-KR	Republic of Korea	ANTI-PD-L1 ANTIBODY AND IL-7 FUSIONS	10-2019-7022001	25-Jul-19	
54LW-267746-US	United States of America	ANTI-PD-L1 ANTIBODY AND IL-7 FUSIONS	16/482023	30-Jul-19	
54LW-267746-WO	PCT	PD-L1 INHIBITOR AND IL-7 FUSIONS	PCT/CN2018/074121	25-Jan-18	
54LW-267746-WO2	PCT	ANTI-PD-L1 ANTIBODY AND IL-7 FUSIONS	PCT/CN2019/073264	25-Jan-19	
54LW-267762-EP	European Patent Office	ANTIBODIES TO T CELL IMMUNORECEPTOR WITH IG AND ITM DOMAINS (TIGT) AND USES THEREOF	19730103.9	21-Jun-19	
54LW-267762-KR	Republic of Korea	ANTIBODIES TO T CELL IMMUNORECEPTOR WITH IG AND ITM DOMAINS (TIGT) AND USES THEREOF	10-2019-7022002	25-Jul-19	

54LW-267752-US	United States of America	ANTIBODIES TO T CELL IMMUNORECEPTOR WITH IG AND ITIM DOMAINS (TIGIT) AND USES THEREOF	16/483270	6-Aug-19
54LW-267752-WO	PCT	ANTIBODIES TO T CELL IMMUNORECEPTOR WITH IG AND ITIM DOMAINS (TIGIT) AND USES THEREOF	PCT/CN2018/075477	6-Feb-18
54LW-267752-WO2	PCT	ANTIBODIES TO T CELL IMMUNORECEPTOR WITH IG AND ITIM DOMAINS (TIGIT) AND USES THEREOF	PCT/CN2019/074775	11-Feb-19
54LW-267784-WO	PCT	ANTI-CD73 ANTI-PD-L1 BISPECIFIC ANTIBODIES	PCT/CN2018/096949	25-Jul-18
54LW-267784-WO2	PCT	ANTI-CD73 ANTI-PD-L1 BISPECIFIC ANTIBODIES	PCT/CN2019/097774	25-Jul-19
54LW-269085-EP	European Patent Office	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	19769368.Z	25-Sep-19
54LW-269085-JP	Japan	ANTI-PD-L1 ANTIBODIES AND USES THEREOF		26-Sep-19
54LW-269085-WO	PCT	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	PCT/CN2018/081079	29-Mar-18
54LW-269085-WO2	PCT	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	PCT/CN2019/080458	29-Mar-19
54LW-271415-WO	PCT	ANTI-FNRI3 ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES	PCT/CN2018/106157	18-Sep-18
54LW-271415-WO2	PCT	ANTI-FNRI3 ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES	PCT/CN2019/106412	18-Sep-19
54LW-271416-WO	PCT	ANTI-CXCL13 ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES AND CANCER	PCT/CN2018/106158	18-Sep-18
54LW-271416-WO2	PCT	ANTI-CXCL13 ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES AND CANCER	PCT/CN2019/106409	18-Sep-19
54LW-295028-WO	PCT	ANTI-PD-L1/ANTI-LAG3 BISPECIFIC ANTIBODIES AND USES THEREOF	PCT/CN2018/101547	21-Aug-18
54LW-295028-WO2	PCT	ANTI-PD-L1/ANTI-LAG3 BISPECIFIC ANTIBODIES AND USES THEREOF	PCT/CN2019/087943	22-May-19
54LW-295028-WO3	PCT	ANTI-PD-L1/ANTI-LAG3 BISPECIFIC ANTIBODIES AND USES THEREOF	PCT/CN2019/101747	21-Aug-19